Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.00027-20.
In patients with renal impairment ( = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations ( = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.
在肾功能不全的患者中（ = 39 例中的 22 例），与肾功能正常的患者相比，利奈唑胺、PNU-142300 和 PNU-142586 的血清浓度中位数分别高出 1.6 倍、3.3 倍和 2.8 倍。配对样本中的代谢物浓度与利奈唑胺浓度相关性较差（PNU-142300 为 = 0.26，PNU-142586 为 = 0.06）。利奈唑胺及其代谢物具有潜在的毒性作用基团，值得进一步研究以降低肾功能不全患者的骨髓抑制风险。
